Jiuyou Capital

Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development.

Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases.

Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promote advanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases.

SmartNuclide is dedicated to the discovery, manufacture, and marketing of nuclear medicine diagnostic and therapeutic pharmaceuticals. The company established a number of research and development pathways for radiopharmaceutical medications, including recombinant proteins, imaging, and radiotherapeutic pharmaceuticals.

Linpowave offers millimeter-wave radar detection systems for automobiles, drones, robots, and security. They provide traffic monitoring and road condition detection radar. Their products have been applied in batches, including UAV obstacle avoidance, UAV ground imitation flight, robot SLAM, intelligent driving, and intelligent transportation.

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meet cost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform. OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes. The company was founded in 2018 and was formerly known as Oncologie.

Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meet cost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system.

SenseFuture is a laser radar technology developer, focusing on providing laser radar and machine vision fusion solutions for robots and unmanned vehicles. Based on the detection performance of photoelectric algorithms, it can meet the needs of unmanned environment perception. Beijing Weisen Technology Co., Ltd., which is a robot and unmanned sensory, provides fusion sensing solutions such as laser radar and vision. The company was registered in May 2018. Prior to this, relying on the talent team and environmental platform of Peking University,they have accumulated 2 years of research results in the field of laser radar.

Beijing Tianyishangjia New Material distributes powder-metallurgy brake pads for high-speed rail EMUs, and continues to increase research and development in the domains of carbon-based composite materials, resin-based carbon fiber composite materials, etc. Tianyishangjia New Material focuses on the development of new material technologies, product research and development, and industrial applications in the fields of large transportation and new energy. Tianyishangjia New Material forms four major products including powder metallurgy brake pads, carbon-based composite products, resin-based carbon fiber composite products, and precision manufacturing of large-scale aviation structural parts.